NanoViricides Sees Potential for NV-387 to Combat Metastatic Cancer Resurgence

NanoViricides is a clinical-stage company developing antiviral drugs, including NV-387, for various respiratory viral infections and MPOX/Smallpox infections. The company plans to advance NV-387 into Phase II human clinical trials and is also developing NV-HHV-1 for Shingles treatment.

NanoViricides, Inc., a clinical-stage company focused on developing antiviral drugs, has announced significant progress in its pipeline. The company, listed on the NYSE American under the stock symbol NNVC, is advancing its broad-spectrum antiviral drug NV-387 into Phase II human clinical trials [1]. NV-387 is designed to combat various respiratory viral infections, including RSV, COVID-19, and Influenza, as well as MPOX/Smallpox infections.

NV-387 has demonstrated promising results in reducing inflammation, particularly the cytokine IL-6, which is linked to an increased risk of resurgence of metastatic cancer due to viral infections [2]. The drug's ability to calm the human immune system and protect lungs makes it a potential game-changer in the treatment of cancer patients in remission who suffer from viral infections.

The company's lead drug candidate, NV-387, has successfully completed a Phase I clinical trial and is now moving into Phase II trials. This advancement follows positive results from animal model studies that showed NV-387's effectiveness in protecting lungs against lethal viral infections caused by RSV, Influenza A/H3N2, and other viruses. In contrast, established antiviral drugs like Tamiflu, Rapivab, and Xofluza failed to provide significant lung protection in these studies.

NanoViricides is also developing NV-HHV-1, an advanced drug candidate for the treatment of Shingles. The company's business model is based on licensing technology from TheraCour Pharma, Inc., and it holds a worldwide exclusive perpetual license for several drugs targeting human viral diseases [3].

The path to drug development is lengthy and capital-intensive, and NanoViricides acknowledges the risks and uncertainties associated with its clinical trials and regulatory approvals. However, the company's progress with NV-387 and NV-HHV-1 indicates its commitment to addressing unmet medical needs and developing innovative antiviral therapies.

References:
[1] https://www.morningstar.com/news/accesswire/1061948msn/a-drug-that-could-reduce-metastatic-cancer-resurgence-due-to-its-anti-inflammatory-effects-in-viral-infections-is-in-clinical-trials
[2] https://news.cuanschutz.edu/cancer-center/covid-19-awaken-dormant-cancer-cells
[3] https://www.nanoviricides.com